Health and Healthcare

Dendreon Downgraded by JMP Securities (DNDN)

Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating.  The brokerage sees uncertainties and risks going into an expected meeting FDA meeting over the recent “approvable and request for more data” on its Provenge for the treatment of late-stage prostate cancer.  It was back around April 11 that JMP downgraded the shares to an Outperform rating.  Shares are trading down about 3% at $6.62 in pre-market trading.

Jon C. Ogg
May 24, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.